Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab)

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Opening Hours
Collections
Help Via Email

Electronic Information Resources

Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab)

详细信息查看全文

作者：Masayoshi Souri^a ; Sho Mokuda^b ; ^c ; Hiroshi Inanami^d ; Tsukasa Osaki^a ; Kiyoshi Takasugi^b ; Akitada Ichinose^a ; ^{aichinos@med.id.yamagata-u.ac.jp" class="auth_mail" title="E-mail the corresponding author}
关键词：Acquired coagulation disorders ; Autoimmune diseases ; Chemokines ; Bleeding disorder ; Factor XIII/transglutaminases
刊名：Thrombosis Research
出版年：2016
出版时间：April 2016
年：2016
卷：140
期：Complete
页码：100-105
全文大小：626 K

文摘

•: An antibody to the IL-6 receptor (tocilizumab, TCZ) is an effective treatment for RA.
•: Two RA cases with acquired FXIII deficiency developed bleeding during TCZ treatment.
•: FXIII activity, FXIII-A, -B, and -A₂B₂ antigens were low in 36 TCZ-treated RA cases.
•: The low FXIII levels may result from their impaired synthesis caused by TCZ.
•: TCZ-treated patients may be at an elevated risk of bleeding because of low FXIII.

NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.